Crossing the blood‐brain barrier with nanoparticles

  title={Crossing the blood‐brain barrier with nanoparticles},
  author={Yiqun Zhou and Zhili Peng and Elif S. Seven and Roger M. Leblanc},
  journal={Journal of Controlled Release},

Figures and Tables from this paper

Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges
The authors critically analyze the current in vitro and in vivo models used to evaluate BBB penetration efficacy, including the latest developments in the BBB‐on‐a‐chip models.
Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology
The unique physical and chemical properties of NPs that aid in BBB transport are reviewed and mechanisms of NP transport across the BBB are discussed, including paracellular transport, carrier-mediated transport, and adsorptive- and receptor-mediated transcytosis.
Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics
In this review, nanoparticles (NPs) from simple to developed delivery systems are discussed for the delivery of a drug to the brain and particularly focuses on polymeric nanomaterials that have been used for CNS treatment.
Carbon Dots: A Future Blood–Brain Barrier Penetrating Nanomedicine and Drug Nanocarrier
This review discusses the classification, preparations, structures, properties, and applications of CDs for the treatment of neurodegenerative diseases, especially Alzheimer’s disease (AD) and brain tumor, and discusses future prospects of the CD-based DDS in combination with the development of artificial intelligence and nanorobots.
Nanocarriers as Potential Drug Delivery Candidates for Overcoming the Blood–Brain Barrier: Challenges and Possibilities
A mini-review summarizes key features of the blood–brain barrier (BBB), recapitulates recent advances in the understanding of the BBB, and highlights existing strategies for the delivery of drug to the brain parenchyma.
Crossing the blood–brain barrier with carbon dots: uptake mechanism and in vivo cargo delivery†
Carbon dots prepared from glucose and conjugated to fluorescein (GluCD-F) cross the BBB in zebrafish and rats without the need of an additional targeting ligand and uptake mechanism of GluCDs is glucose transporter-dependent in budding yeast, suggesting glucose-transporter-dependent Glu CD uptake.
Blood-brain barrier crossing using magnetic stimulated nanoparticles.
Blood-brain Barrier Crossing using Magnetic Stimulated Nanoparticles
A physiologically based pharmacokinetic (PBPK) model for intraperitoneal (IP) injected superparamagnetic iron oxide nanoparticles coated by gold and conjugated with poly(ethylene glycol) (PEG) (SPIO-Au-PEG NPs) in mice revealed that the brain bioavailability under the exposure to SMF is slightly better than the control group.
PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP
Manufacturing PLGA NP-based drug products can be achieved with higher efficiency, larger quantity, and better quality with the newly published guidance from the FDA and the progress of current Good Manufacturing Practice (cGMP) technologies.
Lipid nanoparticles for the transport of drugs like dopamine through the blood-brain barrier
Solid lipid nanoparticles able to encapsulate drugs and to cross the blood-brain barrier have been designed to transport and release these drugs into their targets and demonstrate their penetration ability into the brain parenchyma.


Strategies for transporting nanoparticles across the blood-brain barrier.
With wider applications and broader prospection the treatment of brain targeted therapy, nano-medicines have proved to be more potent, more specific and less toxic than traditional drug therapy.
Drug delivery to brain via the blood-brain barrier.
Systemic delivery of blood–brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue
The results suggest that enhancing NP transport across the blood–brain barrier does not necessarily yield proportional pharmacological effects.
PLA/PLGA nanoparticles for delivery of drugs across the blood-brain barrier
Surface modification of PLGA/PLA NPs by coating with surfactants/polymers or covalently conjugating the NPs with targeting ligands has been confirmed to enhance drug delivery across the blood-brain barrier, which indirectly confirms the safety ofPLGA/ PLA NPs used for other purposes than treating CNS diseases.
Nanoparticles as Blood-Brain Barrier Permeable CNS Targeted Drug Delivery Systems
A perspective on the complexity and challenges in fabrication of nanostructures, in vivo nano–bio interactions and also to highlight some of the most used nanosystems for drug delivery into the CNS are offered.
Nanoparticulate systems for brain delivery of drugs.
  • J. Kreuter
  • Biology, Chemistry
    Advanced drug delivery reviews
  • 2001
Pathways for Small Molecule Delivery to the Central Nervous System Across the Blood-Brain Barrier
This review summarizes important concepts of the BBB in normal versus pathophysiology and how this physical, enzymatic, and efflux barrier provides necessary protection to the CNS during drug delivery, and consequently treatment challenging.
Spontaneous penetration of gold nanoparticles through the blood brain barrier (BBB)
It is proved that gold nanoparticles (AuNPs) penetrate the blood brain barrier in rats to reach brain regions and is spontaneous without the application of an external field.
Theranostic quantum dots for crossing blood–brain barrier in vitro and providing therapy of HIV-associated encephalopathy
The use of functionalized QDs for crossing the blood–brain barrier and treating brain disease is discussed and the theranostic QDs offers a strategy to significantly improve the effective dosages of drugs to transverse across the BBB and orientate to the targets inside the brain.
Nanoparticle transport across the blood brain barrier
This review focuses on the application of nanomedicines to neurodegenerative disorders and to other brain pathologies as epilepsy, infectious diseases, multiple sclerosis, lysosomal storage disorders, strokes.